Induction therapy with intercalated TKI and chemotherapy in NSCLC with activating EGFR mutation in stages II-IIIB: NeoIntercal
F Griesinger, M Sebastian, M Serke, C Grohé, L Hillejan, B Passlick, N Reinmuth, U Graeven, S Radke, A Karatas, M Tiemann, T Overbeck · Pneumologie · 2016 · Heft 02
Bibliografische Angaben
Zusammenfassung
Introduction: EGFR TKI treatment is standard of care in patients with metastasized NSCLC carrying an activating EGFR mutation. 1st and 2nd generation agents lead to response rates of up to 70% in metastatic EGFRM+ NSCLC. Recently, new focus has been shed on intercalated regimens of chemotherapy and TKI showing improved PFS as well as OS in the metastatic setting in an unselected Asian population (Wu et al. 2013). Response is a predictor of PFS and OS in limited and locally advanced NSCLC. Chemotherapy induction alone leads to pCR rates of no more than 15%. No data have been generated for induction therapy includ…
